Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axitinib Poised To Join Pfizer's RCC Drug Portfolio In 2012

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Pfizer Inc.'s second-generation VEGF inhibitor axitinib has been granted a standard 10-month review by FDA for the second-line treatment of advanced renal cell carcinoma, positioning it for a potential launch in the first half of 2012.
Advertisement

Related Content

Astellas Pays $125MM Up-Front To Share Rights To AVEO's Tivozanib
RCC Market Snapshot: In A Crowded Field, What's Next?
RCC Market Snapshot: In A Crowded Field, What's Next?

Topics

Advertisement
UsernamePublicRestriction

Register

PS004775

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel